Vitti Labs Announces FDA Approval of IND Application for Phase II Clinical Trial of Combination Mesenchymal Stem Cell and Exosome Treatment of Novel Corona Virus Infection (COVID-19)

/PRNewswire/ -- Vitti Labs (www.vittilabs.com), an AATB Accredited Tissue Bank focused on Life Science Research, Development and Manufacturing, announced today...

Related Keywords

Missouri ,United States ,Miriam Mckinney ,Philipp Vitti ,Tissue Bank ,Life Science Research ,Vitti Lab ,Drug Administration ,Investigational New Drug ,Umbilical Cord Mesenchymal Stem Cell ,Umbilical Cord Mesenchymal Stem Cell Exosomes ,Acute Respiratory Distress Syndrome ,Novel Corona Virus ,Chief Scientist ,Vitti Labs ,Umbilical Cord Mesenchymal Stem Cells ,Stem Cells ,Mesenchymal Stem Cells ,